Indium: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: January 2, 2026🚩 Report this page

Indium

Active ingredient

GB MHRA

Drug class: -
Availability: See label
Markets covered: 1
Products on record: 2

Overview

Indium is an active pharmaceutical ingredient. The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	2	January 2, 2026

GBUnited Kingdom· MHRA

2 products

Uses

GBOfficial regulatory label· revised January 2, 2026[1]

This medicinal product is for diagnostic use only. Cisternoscintigraphy: • Detection of obstructions in cerebrospinal flow. • Differentiation between normal pressure hydrocephalus and other forms of hydrocephalus. • Detection of leaks of cerebrospinal fluid (rhinorrhoea or otorrhoea).

How to take

Sources & citations

[1]MHRA (UK) · PL122880005 · revised January 2, 2026

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised January 2, 2026[1]

Performing a lumbar or occipital puncture may cause adverse reactions which are usually of a mild nature. The symptoms include headache and signs of meningeal irritation, which as a rule improve within 48 hours. Aseptic meningitis and fever have been reported.
If, in the case of suboccipital administration, the radiopharmaceutical is deposited in the immediate vicinity of those places where cerebral nerves exit from the brainstem, the n. oculomotoris, the n. facialis and the n. vestibulocochlearis may be activated causing transitory effects like ptosis of the eyelid, tinnitus or drooping of a corner of the mouth.
Exposure to ionising radiation is linked with cancer induction and a potential for development of hereditary defects. For diagnostic nuclear medicine investigations the current evidence suggests that these adverse effects will occur with low frequency because of the low radiation doses incurred.
8 mSv when the maximal recommended activity for adults of 20 MBq is administered these adverse reactions are expected to occur with a low probability. Higher doses may be justified in some clinical circumstances. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard

GBOfficial regulatory label· Warnings and precautions· revised January 2, 2026[1]

Potential for hypersensitivity or anaphylactic reactions If hypersensitivity or anaphylactic reactions occur, the administration of the medicinal product must be discontinued immediately and intravenous treatment initiated, if necessary.
To enable immediate action in emergencies, the necessary medicinal products and equipment such as endotracheal tube and ventilator must be immediately available. Individual benefit/risk justification For each patient, exposure to ionising radiation must be justifiable on the basis of likely benefit.
The activity administered must be such that the resulting radiation dose is as low as reasonably achievable bearing in mind the need to obtain the intended diagnostic result. Renal impairment/Hepatic impairment Careful consideration of the benefit risk ratio in these patients is required since an increased radiation exposure is possible.
2. Careful consideration of the indication is required since the effective dose per MBq is higher than in adults (see section 11) Patient preparation The patient should be well hydrated before the start of the examination and urged to void as often as possible during the first hours after the examination in order to reduce radiation.
Interpretation of images In a high percentage of patient studies extra-arachnoidal activity is seen due to failed lumbar puncture or to puncture leaks. This might cause false-negative results to occur. A control scan at the injection site for detecting extra-arachnoidal activity is recommended.
Specific warnings This radiopharmaceutical may be used and administered only by authorised persons. Radiopharmaceuticals intended for administration to patients should be prepared by the user in a manner which satisfies both radiological safety and pharmaceutical quality requirements.
e. it is essentially ‘sodium- free’.

This is not medical advice. Consult a qualified healthcare professional.